CREATE, Monash Partner to Advance In Vivo CAR-T Platform
CAMBRIDGE, Mass., July 31, 2026 CREATE Medicines has announced a strategic research collaboration and exclusive worldwide licensing agreement with...
Curis
Advertisement
Curis Advances TakeAim CLL Trial with First Patients Dosed
LEXINGTON, Mass., July 30, 2026 Curis, Inc. has reached an important clinical milestone by successfully dosing the first five...
Curis Achieves Early Enrollment in Phase 2 CLL Trial
LEXINGTON, Mass., July 6, 2026 Curis, Inc. announced an important enrollment milestone for its Phase 2 TakeAim CLL clinical...
Curis Reaffirms Initial Patient Dosing Timeline for TakeAim CLL Trial
LEXINGTON, Mass., June 26, 2026 Curis, Inc. announced continued progress in its Phase 2 TakeAim CLL clinical trial, confirming...
Advertisement
